Overall market sentiment has been high on Actinium Pharmaceuticals Inc (ATNM) stock lately. ATNM receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Actinium Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATNM!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With ATNM Stock Today?
Actinium Pharmaceuticals Inc (ATNM) stock is trading at $9.39 as of 2:10 PM on Friday, Mar 22, an increase of $0.28, or 3.07% from the previous closing price of $9.11. The stock has traded between $9.04 and $9.86 so far today. Volume today is high. So far 691,596 shares have traded compared to average volume of 372,877 shares.
To screen for more stocks like Actinium Pharmaceuticals Inc click here.
More About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Click Here to get the full Stock Report for Actinium Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
